DBV submits FDA BLA for VIASKIN Peanut Patch in children aged 4-7
DBV Technologies submitted a BLA to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review; the FDA previously granted Breakthrough Therapy designation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.